ArticleAnnals of hematology2025
Routine interventions failed to provide survival benefits for early-stage major salivary gland marginal zone lymphoma in a population-based analysis.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major salivary gland marginal zone lymphoma (MSGMZL) is a rare malignant tumor, predominantly presenting with early-stage (I/II) lesions. Given the scarcity of evidence for treatment efficacy, a comprehensive analysis of the long-term outcomes of various therapeutic approaches in early-stage MSGMZL is warranted. A population-based cohort study was conducted to include patients diagnosed with MSGMZL from 1992 to 2016, using data from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression, propensity score matching (PSM), and stratified analyses were employed. A total of 1,091 early-stage MSGMZL cases were identified, with a median follow-up of 81.0 months. Key prognostic factors for overall survival included age over 60 years at diagnosis (hazard ratio [HR], 5.99; 95% confidence interval [CI], 4.36-8.24), diagnosis before 2005 (HR, 1.46; 95% CI, 1.10-1.95), and the presence of coexisting malignancy (HR, 1.61; 95% CI, 1.27-2.04). Disease-specific survival was adversely affected by age over 60 years at diagnosis (HR, 4.25; 95% CI, 2.34-7.75) and by the year of diagnosis before 2005 (HR, 1.98; 95% CI, 1.06-3.67). PSM revealed no differences in survival outcomes among conventional interventions. Subgroup analyses indicated that patients diagnosed after 2005 exhibited improved survival curves, suggesting the potential impact of novel therapeutic strategies. Our retrospective analysis indicates that conventional treatments do not confer a survival advantage for patients with early-stage MSGMZL. These findings underscore the urgent need for innovative therapeutic approaches and highlight the direction for future research aimed at improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.